"The discovery of GSK221149A: a potent and selective oxytocin antagonist". Bioorganic & Medicinal Chemistry Letters. 18 (1): 90–4. January 2008. doi:10.1016/j.bmcl.2007.11.008. PMID18032036. Unknown parameter |displayauthors= ignored (bantuan)
Borthwick AD, Liddle J (January 2013). "Retosiban and Epelsiban: Potent and Selective Orally available Oxytocin Antagonists". Dalam Domling A (penyunting). Methods and Principles in Medicinal Chemistry: Protein-Protein Interactions in Drug Discovery. Weinheim: Wiley-VCH. m/s. 225–256. doi:10.1002/9783527648207.ch10. ISBN978-3-527-33107-9.
"The Design of Orally Bioavailable 2,5-Diketopiperazine Oxytocin Antagonists: From Concept to Clinical Candidate for Premature Labour". Medicinal Research Reviews. 31 (4): 576–604. July 2011. doi:10.1002/med.20193. PMID20027670.
"Use of a novel and highly selective oxytocin receptor antagonist to characterize uterine contractions in the rat". American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 293 (1): R299–305. 2007. doi:10.1152/ajpregu.00057.2007. PMID17395790.
"The discovery of GSK221149A: a potent and selective oxytocin antagonist". Bioorganic & Medicinal Chemistry Letters. 18 (1): 90–4. January 2008. doi:10.1016/j.bmcl.2007.11.008. PMID18032036. Unknown parameter |displayauthors= ignored (bantuan)
"The Design of Orally Bioavailable 2,5-Diketopiperazine Oxytocin Antagonists: From Concept to Clinical Candidate for Premature Labour". Medicinal Research Reviews. 31 (4): 576–604. July 2011. doi:10.1002/med.20193. PMID20027670.
"Use of a novel and highly selective oxytocin receptor antagonist to characterize uterine contractions in the rat". American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 293 (1): R299–305. 2007. doi:10.1152/ajpregu.00057.2007. PMID17395790.
